MTFB Motif Bio Plc

TIDMMTFB

RNS Number : 4434T

Motif Bio PLC

20 July 2015

Motif Bio plc

("Motif" or the "Company")

Exercise of Options

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will issued 25,147 ordinary shares of 1 penny each ("Option Shares") in settlement of options that have been exercised by a former employee. The options were exercised at prices of US $0.20877 and $0.69589 per ordinary share for total consideration of US $8,750.

Admission to trading on AIM ("Admission") of the Option Shares, which will rank pari passu with the existing Ordinary Shares, has been applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 23 July 2015.

Total Voting Rights

Following Admission, the total issued share capital of the Company will be 64,346,216 Ordinary Shares with one voting right each. The Company does not hold any shares in treasury.

Accordingly, the total voting rights in the Company will be 64,346,216. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules of the UK Financial Conduct Authority.

For further information please contact

Enquiries

 
 Motif Bio plc                          info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  Robert Bertoldi (Chief Financial 
  Officer) 
  www.motifbio.com 
 
 Zeus Capital Limited (Nominated        +44 (0) 207 
  Advisor and Broker)                    533 7727 
 Phil Walker / John Treacy 
  Dominic Wilson 
 Northland Capital Partners Limited     +44 (0) 20 
  (Broker)                               7382 1100 
 Gerry Beaney/David Hignell 
  John Howes/Mark Treharne (Broking) 
 Plumtree Capital Limited (Financial 
  Advisor)                              +44 (0) 207 
  Stephen Austin                         183 2493 
 
 
                                          +49 (0) 89 
   MC Services AG (Public Relations)      210 2280 
   Raimund Gabriel                        +44 (0) 207 
   Shaun Brown                            148 5998 
 Yellow Jersey PR Limited (Investor 
  Relations) 
  Dominic Barretto                      +44 (0) 7768 
  Fiona Walker                           537 739 
 

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPKODPOBKDDOD

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024